Meglumine antimoniate indications and usage: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 4: | Line 4: | ||
==Indications and Usage== | ==Indications and Usage== | ||
Treatment of: | Treatment of: | ||
* Visceral leishmaniasis | |||
* Cutaneous leishmaniasis (except for L. aethiopica infections, which are unresponsive) | |||
* Diffuse cutaneous leishmaniasis due to L. amazonensis | |||
<ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Leishmaniasis: Meglumine antimoniate and sodium stibogluconate | url = http://apps.who.int/medicinedocs/en/d/Jh2922e/2.4.1.html#Jh2922e.2.4.1 | publisher = | date = | accessdate = }}</ref> | * Cutaneous and mucocutaneous leishmaniasis due to L. braziliensis.<ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Leishmaniasis: Meglumine antimoniate and sodium stibogluconate | url = http://apps.who.int/medicinedocs/en/d/Jh2922e/2.4.1.html#Jh2922e.2.4.1 | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Latest revision as of 03:40, 7 January 2014
| Meglumine Antimoniate |
|---|
| GLUCANTIM® WHO Prescribing Information |
| Description |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Dosage and Administration |
| How Supplied |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Indications and Usage
Treatment of:
- Visceral leishmaniasis
- Cutaneous leishmaniasis (except for L. aethiopica infections, which are unresponsive)
- Diffuse cutaneous leishmaniasis due to L. amazonensis
- Cutaneous and mucocutaneous leishmaniasis due to L. braziliensis.[1]
References
Adapted from the FDA Package Insert.